Outsourcing in Clinical Trials New England 20147-8 October 2014, Boston, MA
Welcome to the flagship event in our global Outsourcing in Clinical Trials Series. Last year over 400 pharmaceutical, biotechnology and medical device professionals attended Outsourcing in Clinical Trials New England event to learn from case-study based presentations, network with their peers, discover new solutions and services and find answers to all of their clinical challenges.
With such enthusiasm around this conference, this October’s event will once again bring together the industry leaders from within this hub for two days of presentations, case studies, panel discussions and roundtables, alongside the networking opportunity. With over 50 speakers participating, the content will cover all aspects of clinical outsourcing from informed sourcing and efficient contract negotiation through to effective management, monitoring and communication techniques.
We are pleased to announce an additional Speaker has joined the program. Rachel Morgan (Global Head, Clinical Science and Innovation, Translational Medicine, Novartis Institute Biomedical Research) will be joining David Connelly, (Chief Executive Officer, Cmed Group) for a presentation at 4pm on the first day of the event
Whether you are a senior professional in a global pharmaceutical company or a smaller company looking to expand, access to insight and knowledge about the latest pharmaceutical trends is vital.
The Outsourcing Clinical Trial series is growing every year. View the full list of upcoming events to make sure you don’t miss any news. The list of websites will be updated as soon as new events are live so check back regularly
We are always happy to see photos taken at our events! If you have any you would like to submit, please email firstname.lastname@example.org The Arena Team
Primary delegates for this event are those with responsibility for clinical outsourcing decisions and strategy within biotechnology, pharmaceutical, virtual and medical device companies throughout Southern California.
Outsourcing in Clinical Trials New England boasts a fantastic exhibition of clinical service providers and industry specialists. Our exhibition area is already filling up due to the fantastic launch event which took place this year. If you have a service or solution you would like to promote at this event, please use the details below to make contact with our commercial team.
Pfizer has enrolled the first patient in its multicentre Phase II clinical trial of PF-06252616, an experimental, infused, anti-myostatin monoclonal antibody, to treat boys with Duchenne muscular dystrophy (DMD).
Israel-based Mapi Pharma has treated the first patient in its Phase IIa trial of GA Depot being developed to treat relapsing remitting multiple sclerosis (RRMS).
US-based Isis Pharmaceuticals has started Phase I/II trial of ISIS-DMPK to treat patients with myotonic dystrophy type 1 (DM1), a rare genetic neuromuscular disease.
US-based biopharmaceutical firm Anavex Life Sciences has started enrolling patients in a multi-centre Phase IIa clinical trial for ANAVEX 2-73 to treat Alzheimer’s disease (AD).
US-based Ultragenyx Pharmaceutical has started dosing first patient in the pivotal Phase III trial of recombinant human beta-glucuronidase (rhGUS, UX003), an investigational therapy to treat Mucopolysaccharidosis 7 (MPS 7), also known as Sly syndrome…
Boehringer Ingelheim has started patient enrolment in the RE-SPECT ESUS Phase III trial designed to evaluate the efficacy and safety of dabigatran etexilate to prevent recurrent embolic stroke of undetermined source (ESUS).